An anti-Alzheimer’s drug could enhance this high-risk action. Is it worth buying it here?
vTv Therapeutics (VTVT) is a $156 million biopharmaceutical company focused on small molecule drugs for Alzheimer’s, diabetes and inflammatory disorders, all in clinical trials. VTVT has surged 182% over the past year, hitting a two-year high, with strong technical momentum. Wall Street is leaning toward “strong buy” with targets of up to $47, but some…